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Epithelial Overexpression of SOCS-3 in Transgenic
Mice Exacerbates Wound Inflammation in the
Presence of Elevated TGF-b1
Andreas Linke1, Itamar Goren1, Michael R. Bo¨sl2, Josef Pfeilschifter1 and Stefan Frank1
The suppressor of cytokine signaling (SOCS)-3 has been shown to impair proliferation and migration of
keratinocytes. To assess the functional dependency among wound inflammation, SOCS-3 induction in
keratinocytes, and the outcome of healing, we generated a transgenic mouse that specifically overexpresses
SOCS-3 in keratinocytes. Acute wound healing in transgenic mice was severely impaired. Keratinocyte-specific
overexpression of SOCS-3 led to atrophied wound-margin epithelia and augmented the inflammatory response
of wound keratinocytes by an increase in chemokine (MIP-2) and inflammatory enzyme (COX-2 and iNOS)
expression. In addition, wound tissue of transgenic mice showed a prolonged persistence of neutrophils and
macrophages. Remarkably, impaired wounds showed elevated levels of transforming growth factor (TGF)-b1,
which appeared to interfere with healing, as its neutralization markedly improved wound closure in transgenic
mice. Interestingly, administration of a TGF-b-neutralizing antibody increased wound inflammation in
nontransgenic mice but not in transgenic littermates. This study suggests that SOCS-3-driven disturbances in
wound keratinocytes are sufficient to induce inflamed wound conditions that resemble characteristics of
chronic wounds in mice.
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INTRODUCTION
The suppressors of cytokine signaling (SOCS) have been
identified as a family of eight proteins (SOCS-1 to SOCS-7
and cytokine-inducible SH2 domain-containing protein (CIS))
that participate in the control of inflammation by preventing
excessive responses to cytokines (Alexander and Hilton,
2004; Wormald and Hilton, 2004). These proteins do so by
specifically interfering with cytokine-mediated signaling from
hematopoietin transmembrane receptors (Gadina et al.,
2001), which transduce external signals by subsequent
activation of JAK and the signal transducer and activator of
transcription (STAT) family of latent transcription factors (Ihle
and Kerr, 1995; Darnell, 1997). Because successful tissue
repair in adult organisms is associated with tightly controlled
wound inflammation (Martin, 1997; Singer and Clark, 1999;
Martin and Leibovich, 2005), it is not surprising that SOCS-3
expression has been shown to parallel acute as well as
diabetes-impaired, exacerbated inflammatory wound condi-
tions in mice (Goren et al., 2006a). Interestingly, prominent
signals for wound-expressed SOCS-3 were derived from
wound keratinocytes (Goren et al., 2006a).
Regarding this finding, central functions in keratinocyte
biology have recently been connected to the presence of
SOCS-3 in the cells. Here, SOCS-3 function must be viewed in
close conjunction with the activation of the JAK2/STAT-3-
signaling pathway. Constitutively active STAT-3 provoked a
hyperproliferation of keratinocytes and caused a psoriasis-like
phenotype in transgenic mice (Sano et al., 2005), whereas
STAT-3 ablation led to a strong impairment of keratinocyte
migratory potential (Sano et al., 1999). The above-mentioned
STAT-3 functions in the control of keratinocyte proliferation
and migration become inhibited in the presence of SOCS-3.
SOCS-3 efficiently prevented cytokine- (Linke et al., 2009) or
hepatocyte growth factor–mediated activation of STAT-3
(Yamasaki et al., 2003; Tokamura et al., 2005), strongly
suggesting that the inhibitory potency of SOCS-3 derives from
its capability to inactivate the JAK-2/STAT-3 signaling pathway.
In recent years, many approaches to improving the healing
of chronic wounds in humans have been taken. In view of the
fact that topical application of recombinant growth factors
did not turn out to be beneficial (Jeffcoate and Harding,
2003), one can assume that impaired wounds might be
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characterized by a loss of responsiveness in target-cell
populations (Falanga, 2005) due to changes in intracellular
signaling properties. In particular, this has been shown for
fibroblasts derived from human diabetic and venous ulcers,
which showed a decreased proliferation response to growth
factors (Hasan et al., 1997; Loots et al., 2002; Stanley et al.,
2005) or a decreased receptor expression (Kim et al., 2003).
This potential ‘signaling–silencing’ role might be taken over
by SOCS-3 in wound keratinocytes.
At this point, an interesting question emerges that might
provide additional clues for the understanding of the etiology
of chronic wounds. Controlled inflammation of a wound is
considered a key event for successful tissue repair, but excess
inflammation is associated with impaired wound healing
(Eming et al., 2007). However, the causal sequence of
events—inflammation and resident cell responsiveness—might
carry profound implications for our understanding of impaired
healing. What comes first in the deleterious progression of
events? Does an exacerbated inflammation change the
signaling of resident cells in chronic wounds or do changes
in cell responsiveness contribute to the amplification of wound
inflammation? To dissect this question, we overexpressed
SOCS-3 in keratinocytes in transgenic mice. SOCS-3 expres-
sion in keratinocytes led to impaired wounds in the animals,
characterized by atrophied neo-epithelia (Linke et al., 2009)
and an excessive wound inflammation in the presence of
elevated transforming growth factor (TGF)-b1. These findings
evidence an important role of changes in resident cutaneous
cells as an initial cause of disturbed wound healing, changes
that appear to be independent of wound inflammation.
RESULTS
Keratinocyte-specific overexpression of SOCS-3 increases
cytokine expression in skin wounds of tsgn-K5/SOCS-3 mice
In a previous report, we showed that overexpression of
SOCS-3 protein in keratinocytes led to a severe impairment of
skin repair after wounding by interfering with keratinocyte
proliferation and migration (Linke et al., 2009). In the current
study, we examined the inflammatory response in wounds of
transgenic tsgn-K5/SOCS-3 mice. To do so, we determined
the presence of IL-1b and tumor necrosis factor (TNF)-a, both
being prototypic inflammatory mediators at wound sites
(Werner and Grose, 2003). In wounds of tsgn-K5/SOCS-3
mice, we observed a prolonged upregulation of IL-1b
(Figure 1a, upper panels) and TNF-a (Figure 1b, upper
panels) mRNA. In accordance with elevated mRNA levels,
ELISA of wound tissue lysates also revealed a significant
increase of both cytokines in the respective wound tissue of
the transgenic mice (Figures 1a and b, lower panels).
Tsgn-K5/SOCS-3 mice express increased levels of macrophage
inflammatory protein (MIP)-2 at the wound margins
Next, we analyzed the expression of MIP-2 and MCP-1,
which represent prototypical chemokines for the attraction of
neutrophils or monocytes/macrophages, respectively (Luster,
1998). Wounds of transgenic mice showed a strong and
prolonged increase in MIP-2 mRNA expression (Figure 2a,
upper panels) that was translated into a marked difference at
the protein level (lower panel). As shown in Figure 2b, MCP-1
mRNA (upper panels) and protein (lower panel) expression
consistently also showed an increasing trend, particularly at
day 5 of repair in tsgn-K5/SOCS-3 mice, although the
observed differences did not reach significance. However,
wound-margin keratinocytes serve as a major source for MIP-
2 and MCP-1 protein (Gillitzer and Goebeler, 2001) in our
transgenic model (Supplemental Figure S1). Thus, it is
reasonable to point out that we assessed increased chemo-
kine levels (Figure 2) despite markedly reduced keratinocyte
numbers within the atrophied wound margins in transgenic
mice (Linke et al., 2009) (Supplementary Figure S1).
Impaired wounds of tsgn-K5/SOCS-3 mice were populated by
increased numbers of neutrophils and macrophages
Given that MIP-2 and MCP-1 are major chemoattractants for
neutrophils and macrophages, respectively (Luster, 1998), we
asked whether the appearance of these chemokines during
the late stage of acute repair might be translated into a
prolonged infiltration of these cell types. To this end, we
determined the constitutively expressed mRNA species for
lysozyme M (expressed in macrophages) (Figures 3a–c) and
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Figure 1. IL-1b and tumor necrosis factor (TNF)-a expression in disturbed
wounds of tsgn-K5/SOCS-3 mice. RNase protection assays showing IL-1b (a)
or TNF-a (b) mRNA expression in nonwounded skin (ctrl skin) or wound
tissues at different time points after injury of transgenic mice (tsgn-K5/SOCS3)
or their nontransgenic littermates (non-tsgn) as indicated (upper panels).
Hybridization against glyceraldehyde-3-phosphate dehydrogenase is shown
as a loading control. Quantification of the RNase protection assays (Phospho-
Imager PSL counts per 15 mg of total wound RNA) for the 5- and 7-day time
points is shown in the middle panels. **Po0.01; *Po0.05 as indicated
by the brackets. Bars depict means±SEM obtained from wounds (n¼12)
isolated from animals (n¼ 4) of three independent animal experiments (n¼ 3).
IL-1b- and TNF-a-specific ELISA of 5- and 7-day wound lysates isolated
from transgenic (tsgn-K5/SOCS3) and nontransgenic (non-tsgn) mice as
indicated (lower panels). *Po0.05 as indicated by the brackets. Bars
indicate the mean±SEM of 10 wounds (n¼ 10) of 10 animals (n¼10).
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lipocalin (expressed in neutrophils) (Figures 3d–f) to assess the
numbers of the respective cell types in wound tissue (Wetzler
et al., 2000; Goren et al., 2003). Both cell-type markers and the
respective cells were markedly increased in late acute wounds
of tsgn-K5/SOCS-3 mice. These findings were confirmed by the
determination of specific cellular surface marker proteins for
both immune cell types: F4/80 (for macrophages) (Figure 3a,
lower panel) and GR-1 (for neutrophils) (Figure 3d, lower
panel) immunoblots again demonstrated an increased and
prolonged appearance of macrophages and neutrophils in
impaired wounds of transgenic animals. Immunohistochemical
staining of 7-day-old wounds from tsgn-K5/SOCS-3 mice and
non-tsgn littermates again confirmed the observed accumula-
tion of macrophages and neutrophils, particularly in wounds of
transgenic animals (Supplemental Figure S2).
Atrophied wound-margin epithelia overexpress
pro-inflammatory enzymes
To shed more light on the inflammatory conditions present
in disturbed wounds with respect to SOCS-3-expressing
keratinocytes, we measured the pro-inflammatory enzymes
cyclooxygenase (Cox)-2 (Figure 4) and inducible nitric oxide
synthase (iNOS) (Supplemental Figure S3), both of which
have been shown to be expressed in keratinocytes of the
hyperproliferative epithelia during normal wound repair
(Frank et al., 1999; Ka¨mpfer et al., 2003). Cox-2 and iNOS
expression was increased and prolonged after wounding in
transgenic mice, as shown for Cox-2 at the mRNA (Figure 4a,
upper panel, Figure 4b) and protein levels (Figure 4a, lower
panel, Figure 4c), and could be allocated to wound
keratinocytes (Figure 4c).
TGF-b1 is dysregulated in impaired wounds of tsgn-K5/SOCS-3
mice
To accomplish the analysis of wound inflammation, we
assessed the expression of TGF-b1 at wound sites, as this
cytokine represents a central anti-inflammatory mediator in
mice (Kulkarni et al., 1993). We found an increase in TGF-b1
mRNA levels (Figures 5a and b) and a significant upregulation
of TGF-b1 protein expression (Figure 5c) in disturbed acute
5- and 7-day-old wounds of transgenic mice.
We hypothesized that elevated levels of TGF-b1 protein in
disordered wounds might be part of a regulatory mechanism
that acts to counterbalance a possible loss in responsiveness
of transgenic wound keratinocytes to anti-inflammatory
TGF-b1, as we had observed these cells to be potent producers
of chemokines, Cox-2, and iNOS. By contrast, upon cytokine
stimulation primary SOCS-3-overexpressing keratinocytes
clearly responded to TGF-b1 with a significant reduction in
MCP-1 (Figure 6a), MIP-2 (Figure 6b), and nitrite production
(as a readout for iNOS enzymatic activity) (Figure 6c).
TGF-b1 alone was not able to induce MCP-1, MIP-2, and
nitrite production in the cells (Figures 6a–c, ctrl 24 hours).
In addition, co-incubation of primary cells with cytokines
and a TGF-b-neutralizing antibody did not enhance the
pro-inflammatory response of the cells (Figures 6a–c).
Application of a TGF-b-neutralizing antibody improves
compromised wounds of tsgn-K5/SOCS-3 mice in the presence
of unchanged wound inflammation
Finally, we investigated the role of the TGF-b1 upregulation
in disturbed wounds. Thus, we systemically applied a pan-
specific antibody raised against TGF-b isoforms 1–3 to mice
starting with the day of injury. Unexpectedly, defective
wounds of transgenic mice did not become worse; rather,
they improved upon TGF-b neutralization (Figure 7a). Histo-
logical analyses of wound morphology (Figure 7b) revealed
that antibody treatment resulted in a distinctive contraction of
wound tissue, as the distance between the wound margins
was reduced in transgenic mice upon anti-TGF-b treatment
(3.76±0.44mm (for ctrl-IgG) versus 2.79±0.11mm (for anti-
TGFb); Po0.05; n¼5 wounds). However, anti-TGF-b treat-
ment did not improve the morphology of atrophied wound-
margin epithelia in transgenic mice (Figure 7b), a finding that,
again, might emphasize the antiproliferative potential of
persistently elevated SOCS-3-levels in keratinocytes.
Surprisingly, wound inflammation in tsgn-K5-SOCS-3
mice appeared to be unchanged upon neutralization of
TGF-b. As shown in Figure 8a–c, IL-1b, MIP-2, and Cox-2
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Figure 2. Chemokine expression in wound keratinocytes of tsgn-K5/SOCS-3
mice. RNase protection assays showing macrophage inflammatory protein
(MIP)-2 (a) or MCP-1 (b) mRNA expression in nonwounded skin (ctrl skin)
or wound tissues at different time points after injury from transgenic mice
(tsgn-K5/SOCS3) or their nontransgenic littermates (non-tsgn) as indicated
(upper panels). Hybridization against glyceraldehyde-3-phosphate
dehydrogenase is shown as a loading control. Quantification of the RNase
protection assays (PhosphoImager PSL counts per 15 mg of total wound RNA)
for the 5- and 7-day time points is shown in the middle panels. **Po0.01;
*Po0.05 as indicated by the brackets. Bars depict means±SEM obtained
from wounds (n¼12) isolated from animals (n¼ 4) of three independent
animal experiments (n¼3). MIP-2- and MCP-1-specific ELISA from 5- and
7-day wound lysates isolated from transgenic (tsgn-K5/SOCS3) and
nontransgenic (non-tsgn) mice as indicated (lower panels). *Po0.05;
NS, not significant as indicated by the brackets. Bars indicate the
mean±SEM of 10 wounds (n¼ 10) of 10 animals (n¼ 10).
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mRNA levels did not significantly differ between the anti-
TGF-b-treated and IgG-treated groups of transgenic animals.
Similarly, neutrophil and macrophage infiltrates remained
comparable in these two groups (Supplemental Figure S4). In
contrast, nontransgenic littermates showed a significant
increase in wound inflammation in response to the antibody
treatment (Figures 8a–c), proving the bioavailability and
bioactivity of the applied antibody.
These findings raised the question whether elevated levels
of TGF-b1 observed in wounds of transgenic mice (Figure 5c)
were biologically active. To answer this, we determined the
amount of bioactive TGF-b using an in vitro assay based on
mink lung epithelial cells containing a truncated TGF-b-
sensitive plasminogen activator inhibitor (PAI)-1 promoter
fused to the firefly luciferase reporter gene. This assay allows
quantification of TGF-b in complex biological solutions (Abe
et al., 1994). After calibration of the bioassay (data not
shown), we observed comparable levels of bioactive TGF-b
in wounds of tsgn-K5/SOCS-3 mice and nontransgenic
littermates (Figure 8d). Taken together, our data suggest that
(i) the elevated levels of TGF-b1 in wounds of transgenic mice
comprised only an amount of bioactive TGF-b comparable to
that found in undisturbed wounds of nontransgenic litter-
mates (Figure 8d) and (ii) reduction of bioavailable TGF-b did
not further increase the exacerbated wound inflammation in
transgenic mice.
DISCUSSION
Diabetic ulceration remains a severe clinical complication of
cutaneous tissue regeneration. The risk for diabetic patients of
developing a healing-impaired wound during their lifetime is
as high as 15% (Reiber et al., 1998). Ulceration has a poor
prognosis, with 15–27% of diabetic ulcers resulting in
surgical removal of bone, followed by high perioperative
mortality and 3-year survival rates of only 50% (for review,
see Jeffcoate and Harding, 2003). With respect to data
presented in this paper, it is important to note that diverse and
overlapping factors predispose affected patients to develop-
ing a nonhealing ulcer in the lower extremities. The decisive
underlying changes in diabetic foot ulceration are sensory
and motor neuropathies, which lead to severe dysfunctions in
microcirculation and thus blood supply of tissue, callus
formation, osteopenia, and late ischemic conditions (Jeffco-
ate and Harding, 2003). In particular, microcirculatory
deficiencies interfere with physiological exchanges, normal
oxygen supply, and migration of leukocytes and result in
maldistributed blood flow (Falanga, 2005). It is therefore
reasonable to hypothesize that those severe microanatomical
disturbances in predisposed persons might effect cellular
changes in resident cutaneous cells previous to injury. Once
the skin is broken, the cells are no longer able to exert a
physiological response to the injury signal. This implicates
conditions of distinct cellular changes that might occur
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Figure 3. Immune cell infiltration. RNase protection assay showing lysozyme M (a, upper panel) and lipocalin (d, upper panel) mRNA expression in
nonwounded skin (ctrl skin) or wound tissues at different time points after injury of transgenic mice (tsgn-K5/SOCS3) or their nontransgenic littermates (non-tsgn)
as indicated. Hybridization against glyceraldehyde-3-phosphate dehydrogenase is shown as a loading control. Immunoblots for F4/80 (a, lower panel) or
GR-1 (d, lower panel) protein is shown below. Ponceau S staining was used to control equal loading. Lysozyme M (b, c) or lipocalin (e, f) mRNA
expression during skin repair is shown for the indicated time points. *Po0.05 as indicated. Bars depict means±SEM obtained from wounds (n¼ 12)
isolated from animals (n¼4) of three independent animal experiments (n¼ 3).
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before wounding, rendering cells unresponsive to external
signals (Falanga, 2005). This is strongly supported by recent
data from our laboratory that showed the abrogation of the
signaling machinery from the insulin receptor (IR) in skin
tissue of diabetic ob/ob mice (Goren et al., 2006b). In the
presence of a physiologically expressed IR, skin tissue of
ob/ob mice was characterized by a strong reduction of the
IR-specific adapter molecules IR substrate (IRS)-1 and -2. As
both proteins are pivotal for the signaling downstream of the
activated IR, we found a complete loss of glycogen synthase
(GS) kinase (GSK)-3a/b and GS phosphorylation as a func-
tional consequence of diminished IR signaling. More impor-
tant, readjustment of the diabetic phenotype in ob/ob mice
using recombinant leptin led to a rapid reappearance
of IRS-1 and -2 protein, phosphorylated GSK-3a/b, and GS
(Goren et al., 2006b). These findings suggest that a wounding
situation might occur in an environment of altered cells,
which might become a central constituent for the develop-
ment of a disturbed wound.
In addition, chronic wounds, independent of their etio-
logy, are characterized by a prolonged inflammatory state
that leads to imbalances in protease and cytokine activities
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Figure 4. Cox-2 expression at the wound site. RNase protection assay
(a, upper panels) showing Cox-2 mRNA expression in nonwounded skin
(ctrl skin) or wound tissues at different time points after injury of transgenic
mice (tsgn-K5/SOCS3) or their nontransgenic littermates (non-tsgn) as
indicated. Hybridization against glyceraldehyde-3-phosphate dehydrogenase
is shown as a loading control. Quantification of the RNase protection assays
(PhosphoImager PSL counts per 15 mg of total wound RNA) for the 5- and
7-day time points is shown in (b). *Po0.05 as indicated by the brackets. Bars
depict means±SEM obtained from wounds (n¼12) isolated from animals
(n¼4) of three independent animal experiments (n¼ 3). An immunoblot for
Cox-2 protein is shown (a, lower panel). Ponceau S staining was used to
control equal loading. (c) Quantification of Cox-2 protein expression in 5-day
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brackets. Bars depict means±SEM obtained from wounds (n¼ 4) isolated
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incubated with an antibody directed against Cox-2 protein. Immunopositive
signals are highlighted by yellow arrows. he, hyperproliferative epithelia; sc,
scab. Bar¼ 100mm.
Pr
ob
e
Ct
rl 
sk
in
1-
da
y 
wo
un
d
3-
da
y 
wo
un
d
5-
da
y 
wo
un
d
7-
da
y 
wo
un
d
13
-d
ay
 w
ou
nd
Ct
rl 
sk
in
1-
da
y 
wo
un
d
3-
da
y 
wo
un
d
5-
da
y 
wo
un
d
7-
da
y 
wo
un
d
13
-d
ay
 w
ou
nd
TGFβ1
GAPDH
Non-tsgn tsgn-K5/SOCS3
Non-tsgn tsgn-K5/SOCS3
400
300
200
100
TG
Fβ
1 
m
R
N
A 
ex
pr
es
sio
n
(P
SL
 un
its
 x 
10
)
TG
Fβ
1 
pr
ot
ei
n 
ex
pr
es
sio
n
(pg
 m
l–1
)
*
*
*
**
Non-tsgn
tsgn-K5/SOCS3
Ctrl 1 3 5 7 13
Days
600
400
200
Ctrl Day 5 Day 7
Figure 5. Expression of transforming growth factor (TGF)-b1 during skin
repair. (a) RNase protection assay showing TGF-b1 mRNA expression in
nonwounded skin (ctrl skin) or wound tissues at different time points after
injury of transgenic mice (tsgn-K5/SOCS3) or their nontransgenic littermates
(non-tsgn) as indicated. Hybridization against glyceraldehyde-3-phosphate
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(b). *Po0.05 in comparison to nontransgenic littermates. Bars depict
means±SEM obtained from wounds (n¼ 12) isolated from animals (n¼4)
of three independent animal experiments (n¼ 3). (c) TGF-b1-specific ELISA of
5-day and 7-day wound lysates and nonwounded skin (ctrl) isolated from
transgenic (tsgn-K5/SOCS3) and nontransgenic (non-tsgn) mice as indicated.
**Po0.01; *Po0.05 as indicated by the brackets. Bars depict means±SEM
obtained from wounds (n¼ 12) isolated from animals (n¼ 6).
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(Pierce, 2001). Moreover, wound inflammation is regarded as
being essential for cutaneous homeostasis after injury by
directing the quality of tissue repair (Eming et al., 2007).
Therefore, excessive inflammation appears to be in conjunc-
tion with impaired wound healing in mice (Wetzler et al.,
2000; Goren et al., 2003) and also humans (Rosner et al.,
1995; Loots et al., 1998; Pierce, 2001; Falanga, 2005).
However, the causal connection between inflammation and
potential cellular changes at the wound site in the develop-
ment of chronic wound conditions still remains unsolved.
Uncontrolled wound inflammation might drive alterations in
the responsiveness of wound cells to external signals. Fibro-
blasts from chronic wounds are less sensitive to epidermal
growth factor, insulin-like growth factor-1, basic fibroblast
growth factor, and platelet-derived growth factor–BB with
respect to cell proliferation (Loots et al., 2002) and are
characterized by impaired signaling from the TGF-b receptor II
(Kim et al., 2003). However, an open issue remains: how do
inflammation or altered resident cells interact to bring about
disturbed wound conditions?
To answer this question, we specifically overexpressed
SOCS-3 in keratinocytes. We did so because we had identi-
fied this protein as being expressed in atrophied epithelia in
chronic wounds of ob/ob mice (Goren et al., 2006a). SOCS-3
has been shown to specifically interfere with the JAK2/STAT-
3 signaling pathway in keratinocytes (Yamasaki et al., 2003).
Activation of STAT-3 is clearly involved in the regulation of
keratinocyte proliferation (Sano et al., 2005) or migration
(Sano et al., 1999), and SOCS-3 potently inhibits these
STAT-3-dependent processes (Linke et al., 2009) (Tokamura
et al., 2005; Goren et al., 2006a; Zhu et al., 2008). In
agreement with reported findings, we observed a malfunc-
tioning epithelial response in skin wounds of SOCS-3-
overexpressing mice (Linke et al., 2009).
Keratinocyte-specific expression of SOCS-3 led to exacer-
bated wound inflammation in transgenic mice (this study). In
addition, wound-margin keratinocytes of transgenic mice
showed a pronounced expression of pro-inflammatory
mediators in the presence of TGF-b1 (Supplementary Figure
S1). However, it is unlikely that SOCS-3-overexpressing
keratinocytes were not responsive to TGF-b1, as recombinant
TGF-b1 efficiently blocked the expression of inflammatory
mediators in primary keratinocytes of transgenic mice
in vitro. It is more likely that the enhancement of inflamma-
tion was due to a subclinical population of noncovered
wound sites by microbes, which are sensed by different sets
of Toll-like receptors in keratinocytes. Stimulation of Toll-like
receptors 3, 4, 5, and 9 in keratinocytes mediated the release
of MIP-2 and MCP-1 via activation of NF-kB (Lebre et al.,
2007). Moreover, given that Cox-2 and iNOS also represent
NF-kB-dependent genes (O’Neill, 2006a), the described
activation of NF-kB by Toll-like receptor stimulation (O’Neill,
2006b) might also drive the induction of both genes in wound
keratinocytes. Indeed, subclinical colonization by bacteria
and the formation of biofilms in chronic wounds have been
discussed as critical events interfering with the progression of
the healing process in humans (Edwards and Harding, 2004;
Bjarnsholt et al., 2008).
Moreover, restricted overexpression of SOCS-3 protein in
the epithelial compartment turned normal wound conditions
into conditions reminiscent of those found in diabetic mice:
elevated levels of IL-1b, TNF-a, MIP-2, MCP-1, and Cox-2
and atrophied wound-margin epithelia (Wetzler et al., 2000;
Goren et al., 2003, Ka¨mpfer et al., 2005). Hence, it is
reasonable to argue that altered signaling machinery in
wound keratinocytes inhibited rapid epithelial coverage of
the wound area by interfering with keratinocyte proliferative
and migratory responses. Thus, it seems that inflammation
was prolonged as a consequence of impaired neo-epithelia-
lization but was not the cause of tissue impairments in our
model system.
A second observation of the current study casts doubt on a
causal role of inflammation in impaired healing. Consistent
with the induction of TGF-b1 at the onset of repair (Kane
et al., 1991; Frank et al., 1996), we found elevated levels of
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Figure 6. SOCS-3-overexpressing keratinocytes are responsive to
inflammatory cytokines and transforming growth factor (TGF)-b1. Confluent
primary keratinocytes of transgenic mice (tsgn-K5/SOCS3) or their
nontransgenic littermates (non-tsgn) were assessed for the release of MCP-1
(a), macrophage inflammatory protein (MIP)-2 (b), and nitrite (c) in the
presence or absence of cytokines (40 ngml1 IL-1b, 50 ngml1 tumor
necrosis factor-a, 20 ngml1 IFN-g), TGF-b1 (5 ngml1) or anti-TGF-b
antibody (10 mgml1) after 24 hours as indicated. **Po0.01; *Po0.05 as
indicated by the brackets. Bars depict means±SEM obtained from three
independent cell culture experiments (n¼3).
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TGF-b1 protein in late acute wound tissue of transgenic mice
that exceeded the physiological induction in control animals.
TGF-b1 is known to inhibit keratinocyte proliferation in vivo
(Sellheyer et al., 1993; Amendt et al., 2002). However, our
data suggest that excess TGF-b1 might not essentially
contribute to the observed epithelial defects, as portions of
the elevated levels of TGF-b1 in the wounds of transgenic
mice actually turned out to be in an inactive state. Moreover,
treatment with an anti-TGF-b1 antibody in vivo showed that,
despite neutralization of TGF-b1, wound inflammation did
not increase in transgenic animals as would be expected from
the established anti-inflammatory role of TGF-b1 in mice
(Kulkarni et al., 1993). This finding might be a consequence
of an uncontrolled inflammatory response in transgenic
wounds. It is also possible that the neutralizing antibody
was sequestered by large amounts of inactive TGF-b1 in
those wounds.
Taken together, our data from keratinocyte-specific
SOCS-3-overexpressing mice show that distinct changes in
resident skin cells should be regarded as one basic cause
in the etiology of impaired wounds, which exerts its
deleterious consequences independent of elevated wound
inflammation.
MATERIALS AND METHODS
Generation of transgenic mice (tsgn-K5/SOCS-3)
Generation and analysis of tsgn-K5/SOCS-3 mice have been
previously described in detail (Linke et al., 2009).
Wounding of mice
Wounding of mice was performed as described previously (Stall-
meyer et al., 1999; Frank et al., 1999). Briefly, mice were
anesthetized with a single intraperitoneal injection of ketamine
(80mg kg1 body weight)/xylazine (10mg kg1 body weight). The
hair on the back of each mouse was cut, and the back was
subsequently wiped with 70% ethanol. Six full-thickness wounds
(5mm in diameter, 3–4mm apart) were made on the back of each
mouse by excising the skin and the underlying panniculus carnosus.
The wounds were allowed to form scabs. Skin biopsy specimens
were obtained from the animals 1, 3, 5, 7, and 13 days after
injury. At each time point, an area that included the scab, the
complete epithelial and dermal compartments of the wound
margins, the granulation tissue, and parts of the adjacent muscle
and subcutaneous fat tissue was excised from each wound. As a
control, a similar amount of skin was taken from the backs of
nonwounded mice. Wounds (n¼ 12) isolated from animals (n¼ 4)
were used for RNA analysis. For immunoblot analysis, wounds
Non-tsgn
Ctrl-IgG Ctrl-IgG
Ctrl-IgG
Anti-TGFβ Anti-TGFβ
Anti-TGFβ
SChe
Day 5
Day 5
gt
200.0um
200.0um
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Figure 7. Application of an anti–transforming growth factor(TGF)-b antibody improves wound closure in tsgn-K5/SOCS-3 mice. (a) In situ wound phenotypes
of acute 5-day wounds of tsgn-K5/SOCS-3 mice (right panels) and their nontransgenic littermates (left panels) upon control-IgG or anti-TGF-b treatment.
(b) Hematoxylin-stained frozen sections of 5-day wounds isolated from tsgn-K5/SOCS-3 mice upon control-IgG or anti-TGF-b treatment. The distance between
the hyperproliferative epithelia at the wound margins is indicated by black arrows. The epithelial boundaries are highlighted by a red line. gt, granulation tissue;
he, hyperproliferative epithelium; sc, scab. Bars¼ (a) 5mm, (b) 600mm.
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(n¼ 80) from individual mice (n¼ 4) were used. All animal
experiments were performed according to the guidelines of, and
approved by, the local animal ethics review board (Regierung-
spra¨sidium Darmstadt, Hessen).
Treatment of mice
Mice were administered purified mouse monoclonal antibodies
directed against TGF-b1, -2, and -3 (clone 1D11) (R&D Systems,
Wiesbaden, Germany) or mouse control IgG (R&D Systems) by daily
intraperitoneal injection (2mg kg1 body weight in 0.5ml PBS)
during the wound healing period. The first injection was given
6 hours before wounding.
RNA isolation and RNase protection analysis
RNA isolation from wounds and RNase protection assays were
performed as described previously (Frank et al., 1999, Chomczynski
and Sacchi, 1987). All samples were quantified using PhosphoIma-
ger PSL counts per 15mg of total wound RNA. Glyceraldehyde-3-
phosphate dehydrogenase hybridization served as a loading control.
The hybridization probe (1000 c.p.m.) was used as a size marker,
and hybridization against tRNA was used to show the specificity of
the probe. The cDNA probes were cloned using RT-PCR. The probes
corresponded to nt 481–739 (for IL-1b, GenBank accession number
NM008361), nt 541–814 (for TNF-a, NM_013693), nt 796–1063
(for Cox-2, M64291), nt 3285–3574 (for iNOS; Xie et al., 1992),
nt 63–323 (for MCP-1, NM011333), nt 181–451 (for MIP-2,
NM_009140), nt 1735–1974 (for TGF-b1, NM_011577), nt 23–296
(for lysozyme M, BC002069), nt 816–1481 (for lipocalin, X81627),
and nt 163–317 (for GAPDH, NM002046) of the published
sequences.
Immunohistochemistry
Wounding of mice was performed as described above. Animals were
killed on day 5 or 7 after injury. Biopsies from nonwounded skin
and skin wounds were isolated from the back and embedded
in tissue-freezing medium (TissueTek, Sakura, Zoeterwonde,
The Netherlands). Six-micrometer sections were counterstained with
hematoxylin to document overall wound morphology. Sections were
subsequently incubated overnight at 4 1C with antisera raised against
MIP-2 (Santa Cruz, Heidelberg, Germany), MCP-1 (R&D Systems),
GR-1 (Ly6G) (Pharmingen, Hamburg, Germany), F4/80 (AbD
Serotex, Hamburg, Germany), Cox-2 (Santa Cruz), or iNOS (Santa
Cruz). Primary antibodies were detected using a biotinylated
secondary antibody. The slides were subsequently stained with
the avidin–biotin–peroxidase complex system (Santa Cruz) using 3,
3-diaminobenzidine-tetra-hydrochloride as a chromogenic sub-
strate. Finally, sections were counterstained with hematoxylin and
mounted.
Determination of wound keratinocyte numbers
Low-magnification ( 40) photographs of sections were analyzed
for total keratinocyte cell numbers within the neo-epithelia of
nontransgenic and tsgn-K5/SOCS-3 mice by counting hematoxylin-
stained keratinocyte nuclei.
Preparation of protein lysates and western blot analysis
Skin tissue biopsies were homogenized in lysis buffer (1% Triton
X-100, 20mM Tris-HCl pH 8.0, 137mM NaCl, 10% glycerol, 1mM
dithiothreitol, 10mM NaF, 2mM Na3VaO4, 5mM ethylenediamine-
tetraacetic acid, 1mM phenylmethylsulfonyl fluoride, 5ngml1 apro-
tinin, 5ngml1 leupeptin). Extracts were cleared by centrifugation.
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Protein concentrations were determined using the BCA Protein Assay
Kit (Pierce, Rockford, IL). Fifty micrograms of total protein from skin or
cellular lysates was separated using SDS gel electrophoresis. After
transfer to a nitrocellulose membrane, specific proteins were detected
using antisera raised against GR-1 (Ly6G) (Pharmingen), F4/80 (AbD
Serotec), Cox-2, iNOS (Santa Cruz), and b-actin (Sigma, Taufkirchen,
Germany). A secondary antibody coupled to horseradish peroxidase
and the enhanced chemiluminescence (ECL) detection system were
used to visualize the proteins. In addition, we performed direct
quantification of immunoblots using the Pharos Imaging system (Bio-
Rad, Munich, Germany) according to the manufacturer’s instructions.
Phenylmethylsulfonyl fluoride, dithiothreitol, aprotinin, NaF, and
Na3VaO4 were from Sigma. Leupeptin and okadaic acid were from
BioTrend (Cologne, Germany). The ECL detection system was obtained
from Amersham (Freiburg, Germany).
Culturing of primary keratinocytes
Primary keratinocytes of nontransgenic and tsgn-K5/SOCS-3 mice
were isolated from the skin of newborn mice (1–3 days) by overnight
incubation using dispase (2.4Uml1, 4 1C). After dispase digestion,
the epidermal layer could be separated from the dermis; it was then
treated with trypsin (0.04%)/EDTA (0.03%) for an additional
7minutes to disaggregate cells. After filtration (70 mm; Falcon,
Becton Dickinson Labware, Heidelberg, Germany), keratinocytes
were collected by centrifugation (210 g, 2minutes) and plated onto
collagen IV-coated dishes. Cells were grown on nonsupplemented
keratinocyte basal medium (KBM; PromoCell, Heidelberg, Ger-
many) or keratinocyte growth medium (KGM), supplemented by the
supplier (PromoCell). Confluent keratinocytes were stimulated with
a combination of cytokines (40 ngml1 IL-1b, 50 ngml1 TNF-a,
20 ngml1 IFN-g; Roche, Mannheim, Germany), TGF-b1 (5ngml1;
PeproTech, Hamburg, Germany), or an antibody directed against
TGF-b1, -2, and -3 (clone 1D11) (10 mgml1; R&D Systems).
In vitro assay to determine TGF-b bioactivity from wound
lysates
TGF-b bioactivity was determined using an in vitro assay based on
mink lung epithelial cells containing a truncated TGF-b-sensitive
plasminogen activator inhibitor (PAI)-1 promoter fused to the firefly
luciferase reporter gene (Abe et al., 1994) and additional incubation
with an anti-TGF-b1, -2, and -3 antibody (clone 1D11) (125 mgml1;
R&D Systems). Wounds were homogenized in ice-cold PBS and
mink cells were stimulated with wound lysates (840 mgml1). After
20 hours, the cells were washed and lysed in order to determine
luciferase activity according to the standard protocol of the supplier
(Luciferase Assay System; Promega, Mannheim, Germany).
ELISA
Quantification of murine MIP-2, MCP-1, IL-1b, TNF-a, or TGF-b1 was
performed using the respective murine Quantikine ELISA kit (R&D
Systems) according to the manufacturer’s instructions. To allow subse-
quent ELISA of TGF-b1 from wounds, we processed wound lysates
by homogenizing isolated wound tissues in RIPA buffer (Pierce).
Nitrite determination
Nitrite as a readout for iNOS enzymatic activity was determined
from cell culture supernatants using the Griess reaction (Green et al.,
1982).
Statistical analysis
Data are shown as means±SEM. Data analysis was carried out using
the unpaired Student t-test with raw data.
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